Long-term effectiveness and safety of deucravacitinib for psoriasis: a 52-week real-world study of genital, scalp and nail lesions.

Abstract

Background: The long-term (around 1-year) effectiveness and safety of deucravacitinib for the treatment of psoriasis have not been extensively studied in real-world settings, particularly in difficult-to-treat areas, such as the genital, scalp and nail regions.

Objectives: To evaluate the 52-week real-world effectiveness and safety of deucravacitinib in patients with moderate-to-severe psoriasis of the genital, scalp and nail regions.

Methods: This prospective study analysed 104 patients with moderate-to-severe plaque psoriasis treated with deucravacitinib. Clinical scores, Psoriasis Area and Severity Index (PASI), both static and site-specific Physician Global Assessment (PGA), Dermatology Life Quality Index (DLQI) and laboratory inflammatory indices were assessed during a 52-week period.

Results: Deucravacitinib decreased clinical severity scores, and the decrease was sustained for 52 weeks. At week 52, 86% (37/43), 63% (27/43) and 26% (11/43) of patients achieved PASI 75, PASI 90 and PASI 100 reductions (representing a ≥ 75%, ≥ 90% or 100% improvement from baseline), respectively. Deucravacitinib reduced the PGA scores for the genital, scalp and nail regions, as well as the DLQI. Among the patients who completed the 52-week treatment, no significant impact on laboratory inflammatory indices was observed, and no severe or lethal adverse events were reported. Not all patients completed the full 52-week treatment period, as some discontinued early due to adverse events or for other reasons.

Conclusions: Deucravacitinib may be a promising long-term treatment option for psoriasis, demonstrating sustained effectiveness and safety, including in difficult-to-treat areas, such as the genital, scalp and nail regions in real-world clinical practice.